Stoke Therapeutics (STOK)
$11.66
+0.41
(+3.64%)▲
Insights on Stoke Therapeutics
Decreasing Revenue
Revenue is down for the last 2 quarters, 3.30M → 2.80M (in $), with an average decrease of 15.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -24.54M → -26.95M (in $), with an average decrease of 9.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 5.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 303.8%
Performance
- $11.08$12.03$11.66
4.97%
Downside
Day's Volatility :7.9%
Upside
3.08%
- $3.35$16.40$11.66
71.27%
Downside
52 Weeks Volatility :79.57%
Upside
28.9%
Returns
| Period | Stoke Therapeutics | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 140.91% | 1.7% | 0.0% |
6 Months | 233.14% | 11.3% | 0.0% |
1 Year | 43.77% | 5.4% | 1.3% |
3 Years | -64.12% | 13.9% | -22.1% |
Highlights
Market Capitalization | 583.4M |
Book Value | $3.48 |
Earnings Per Share (EPS) | -2.38 |
Wall Street Target Price | 23.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -1055.89% |
Return On Assets TTM | -29.62% |
Return On Equity TTM | -60.8% |
Revenue TTM | 8.8M |
Revenue Per Share TTM | 0.2 |
Quarterly Revenue Growth YOY | -14.299999999999999% |
Gross Profit TTM | 12.4M |
EBITDA | -112.3M |
Diluted Eps TTM | -2.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.31 |
EPS Estimate Next Year | -2.52 |
EPS Estimate Current Quarter | -0.63 |
EPS Estimate Next Quarter | -0.61 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 103.0%
Technicals Summary
Sell
Neutral
Buy
Stoke Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Stoke Therapeutics | 79.38% | 233.14% | 43.77% | -64.12% | -54.4% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Stoke Therapeutics | NA | NA | NA | -2.31 | -0.61 | -0.3 | NA | 3.48 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Stoke Therapeutics | Buy | $583.4M | -54.4% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Skorpios Trust
32.35%RTW INVESTMENTS, LLC
9.25%Redmile Group, LLC
8.67%COWEN AND COMPANY, LLC
8.33%Morgan Stanley - Brokerage Accounts
7.55%Goldman Sachs Group Inc
6.23%
Corporate Announcements
Stoke Therapeutics Earnings
Stoke Therapeutics’s price-to-earnings ratio stands at None
Read More
Company Information
stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.
Organization | Stoke Therapeutics |
Employees | 110 |
CEO | Dr. Edward M. Kaye M.D., Ph.D. |
Industry | Health Technology |
